These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20644468)

  • 1. A practical approach to the metabolic syndrome: review of current concepts and management.
    Tota-Maharaj R; Defilippis AP; Blumenthal RS; Blaha MJ
    Curr Opin Cardiol; 2010 Sep; 25(5):502-12. PubMed ID: 20644468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Another look at the results of the JUPITER trial.
    Kappagoda CT; Amsterdam EA
    Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
    Davidson M
    Am J Cardiol; 2008 Dec; 102(12A):19L-27L. PubMed ID: 19084086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical "ABCDE" approach to the metabolic syndrome.
    Blaha MJ; Bansal S; Rouf R; Golden SH; Blumenthal RS; Defilippis AP
    Mayo Clin Proc; 2008 Aug; 83(8):932-41. PubMed ID: 18674478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia.
    Ali YS; Linton MF; Fazio S
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):142-6. PubMed ID: 18316949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin prescription in men and women at cardiovascular risk: to whom and when?
    Brugts JJ; Deckers JW
    Curr Opin Cardiol; 2010 Sep; 25(5):484-9. PubMed ID: 20625281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
    Spatz ES; Canavan ME; Desai MM
    Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan H; Yetkin E
    Int J Cardiol; 2006 Jun; 110(2):276-7. PubMed ID: 16364471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metabolic syndrome.
    Wagh A; Stone NJ
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):213-28. PubMed ID: 15151470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.